Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori Eradication
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
;
: 174-179, 2023.
Article
Dans Coréen
| WPRIM
| ID: wpr-1003023
ABSTRACT
The escalating prevalence of clarithromycin resistance in cases of Helicobacter pylori, insufficient acid suppression, and pharmacodynamic variations secondary to inter-individual differences in CYP2C19 polymorphism collectively contribute to suboptimal eradication rates observed with proton pump inhibitor (PPI)-based therapy. Compared with PPIs, potassium-competitive acid blockers (PCABs) produce rapid, potent, and long-lasting suppression of gastric acid through reversible inhibition of gastric H+, K+-ATPase. PCAB-based therapy results in significant inhibition of acid secretion and has therefore emerged as a novel and effective approach for H. pylori eradication. In this study, we review the efficacy and safety profile of PCAB-based eradication regimens comprising vonoprazan, tegoprazan, and fexuprazan.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Coréen
Texte intégral:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Année:
2023
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS